Pharmacological characterization of a novel, potent, selective, and orally active fatty acid amide hydrolase inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide] in rats: Potential for the treatment of inflammatory pain

Recently, we identified a novel fatty acid amide hydrolase (FAAH) inhibitor, PKM‐833 [(R)‐N‐(pyridazin‐3‐yl)‐4‐(7‐(trifluoromethyl)chroman‐4‐yl)piperazine‐1‐carboxamide]. The aim of the present study is to characterize the pharmacological profile of PKM‐833 in vitro and in vivo. PKM‐833 showed potent inhibitory activities against human and rat FAAH with IC50 values of 8.8 and 10 nmol/L, respectively, 200‐fold more selectivity against other 137 molecular targets, and irreversible mode of action. In pharmacokinetic and pharmacodynamic studies, PKM‐833 showed excellent brain penetration and good oral bioavailability, and elevated anandamide (AEA) concentrations in the rat brain. These data indicate that PKM‐833 is a potent, selective, orally active, and brain‐penetrable FAAH inhibitor. In behavioral studies using rat models, PKM‐833 significantly attenuated formalin‐induced pain responses (3 mg/kg) and improved mechanical allodynia in complete freund's adjuvant (CFA)‐induced inflammatory pain (0.3‐3 mg/kg). On the other hand, PKM‐833 did not show the analgesic effects against mechanical allodynia in chronic constriction injury (CCI)‐induced neuropathic pain up to 30 mg/kg. Regarding side effects, PKM‐833 had no significant effects on catalepsy and motor coordination up to 30 mg/kg. These results indicate that PKM‐833 is a useful pharmacological agent that can be used to investigate the role of FAAH and may have therapeutic potential for the treatment of inflammatory pain without undesirable side effects.

[1]  B. Parsons,et al.  The efficacy of pregabalin for the treatment of neuropathic pain in Japanese subjects with moderate or severe baseline pain , 2019, Journal of pain research.

[2]  Cheng Zhou,et al.  Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain. , 2019, Anesthesia and analgesia.

[3]  L. Kiss,et al.  Discovery of a Potent, Long‐Acting, and CNS‐Active Inhibitor (BIA 10‐2474) of Fatty Acid Amide Hydrolase , 2018, ChemMedChem.

[4]  F. Gado,et al.  Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis , 2018, Medicines.

[5]  W. Masocha.  Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models , 2018, Pain research & management.

[6]  G. Griebel,et al.  The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents , 2018, Scientific Reports.

[7]  T. Ozawa,et al.  In vitro and in vivo pharmacological characterization of ASP8477: A novel highly selective fatty acid amide hydrolase inhibitor , 2017, European journal of pharmacology.

[8]  Á. Párdutz,et al.  Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine , 2017, International journal of molecular sciences.

[9]  P. Blahunka,et al.  The MOBILE Study—A Phase IIa Enriched Enrollment Randomized Withdrawal Trial to Assess the Analgesic Efficacy and Safety of ASP8477, a Fatty Acid Amide Hydrolase Inhibitor, in Patients with Peripheral Neuropathic Pain , 2017, Pain medicine.

[10]  G. Yudowski,et al.  Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease , 2017, Front. Cell. Neurosci..

[11]  S. Maehara,et al.  Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM‐042 [(E)‐4‐(2‐(2‐(5,8‐dimethyl‐[1,2,4]triazolo[1,5‐a]pyrazin‐2‐yl)vinyl)‐6‐(pyrrolidin‐1‐yl)pyrimidin‐4‐yl)morpholine] in rats: potential for the treatment of schizophrenia , 2016, Pharmacology research & perspectives.

[12]  T. Dyhring,et al.  NS383 Selectively Inhibits Acid‐Sensing Ion Channels Containing 1a and 3 Subunits to Reverse Inflammatory and Neuropathic Hyperalgesia in Rats , 2016, CNS neuroscience & therapeutics.

[13]  Sandy J. Wilson,et al.  Preclinical Characterization of the FAAH Inhibitor JNJ-42165279. , 2015, ACS medicinal chemistry letters.

[14]  Mellar P. Davis.  Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands , 2014, Expert opinion on investigational drugs.

[15]  Shane W. Krska,et al.  Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain. , 2014, ACS medicinal chemistry letters.

[16]  T. Smart,et al.  An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee , 2012, PAIN®.

[17]  R. Coccurello,et al.  The Novel Reversible Fatty Acid Amide Hydrolase Inhibitor ST4070 Increases Endocannabinoid Brain Levels and Counteracts Neuropathic Pain in Different Animal Models , 2012, Journal of Pharmacology and Experimental Therapeutics.

[18]  R. Craft,et al.  Sex Differences in Cannabinoid 1 vs. Cannabinoid 2 Receptor-Selective Antagonism of Antinociception Produced by Δ9-Tetrahydrocannabinol and CP55,940 in the Rat , 2012, Journal of Pharmacology and Experimental Therapeutics.

[19]  Benjamin F. Cravatt,et al.  Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain , 2011, Journal of Pharmacology and Experimental Therapeutics.

[20]  Raymond C Stevens,et al.  Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. , 2009, Chemistry & biology.

[21]  Sandy J. Wilson,et al.  Biochemical and Biological Properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a Mechanism-Based Inhibitor of Fatty Acid Amide Hydrolase , 2009, Anesthesia and analgesia.

[22]  Raymond C Stevens,et al.  Structure-guided inhibitor design for human FAAH by interspecies active site conversion , 2008, Proceedings of the National Academy of Sciences.

[23]  Jean M. Severin,et al.  A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase , 2007, Journal of Neuroscience Methods.

[24]  L. Petrocellis,et al.  Analgesic actions of N‐arachidonoyl‐serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors , 2007, British journal of pharmacology.

[25]  D. Barrett,et al.  Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. , 2007, Analytical biochemistry.

[26]  Sandy J. Wilson,et al.  Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms , 2006, British journal of pharmacology.

[27]  D. Piomelli,et al.  Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models , 2006, British journal of pharmacology.

[28]  M. Versavel,et al.  Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13‐week, randomized trial , 2006, Current medical research and opinion.

[29]  T. Ogihara,et al.  Pharmacological profiles of the novel analgesic M58996 in rat models of persistent and neuropathic pain. , 2006, Journal of pharmacological sciences.

[30]  J. D. Clark,et al.  A fluorescence-based assay for fatty acid amide hydrolase compatible with high-throughput screening. , 2005, Analytical biochemistry.

[31]  Alan Saghatelian,et al.  Functional disassociation of the central and peripheral fatty acid amide signaling systems. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  B. Cravatt,et al.  Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia , 2004, Pain.

[33]  M. Elphick,et al.  Comparative analysis of fatty acid amide hydrolase and cb1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling , 2003, Neuroscience.

[34]  L. Urbán,et al.  The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. , 2001, Pain.

[35]  B. Cravatt,et al.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Urbán,et al.  The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain , 2001, Pain.

[37]  J. Hughes,et al.  Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones? , 1999, PAIN.

[38]  S. McCleary,et al.  Gabapentin (neurontin) and S‐(+)‐3‐isobutylgaba represent a novel class of selective antihyperalgesic agents , 1997, British journal of pharmacology.

[39]  Stephen P. Mayfield,et al.  Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides , 1996, Nature.

[40]  T. Yaksh,et al.  Quantitative assessment of tactile allodynia in the rat paw , 1994, Journal of Neuroscience Methods.

[41]  Gary J. Bennett,et al.  A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man , 1988, Pain.

[42]  D. Dubuisson,et al.  The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats , 1977, Pain.